NYSE:CFX - New York Stock Exchange, Inc. - Common Stock
39.06
-1.53 (-3.77%)
The current stock price of CFX is 39.06 null. In the past month the price increased by 7.54%. In the past year, price decreased by -10.02%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
PH | PARKER HANNIFIN CORP | 27.2 | 91.89B | ||
ITW | ILLINOIS TOOL WORKS | 25.57 | 75.74B | ||
OTIS | OTIS WORLDWIDE CORP | 25.71 | 39.27B | ||
IR | INGERSOLL-RAND INC | 26.93 | 35.09B | ||
XYL | XYLEM INC | 30 | 32.19B | ||
SYM | SYMBOTIC INC | 2395.5 | 28.25B | ||
DOV | DOVER CORP | 21.24 | 25.86B | ||
FTV | FORTIVE CORP | 13.53 | 18.03B | ||
PNR | PENTAIR PLC | 23.64 | 17.58B | ||
SNA | SNAP-ON INC | 16.84 | 16.82B | ||
GGG | GRACO INC | 31.6 | 14.84B | ||
IEX | IDEX CORP | 23.39 | 13.69B |
Colfax Corp. operates as a diversified technology company. The company is headquartered in Wilmington, Delaware and currently employs 16,200 full-time employees. The company went IPO on 2008-05-08. The Company’s segments include Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. Its fabrication technology products are marketed under several brands, including ESAB. The Medical Technology segment develops, manufactures and distributes medical devices and services across the continuum of patient care from injury prevention to joint replacement to the rehabilitation after surgery, injury from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, athletic trainers and other healthcare professionals.
COLFAX CORP
2711 Centerville Road, Suite 400
Wilmington DELAWARE 20701 US
CEO: Matthew L. Trerotola
Employees: 16200
Phone: 13022529160.0
The current stock price of CFX is 39.06 null. The price decreased by -3.77% in the last trading session.
The exchange symbol of COLFAX CORP is CFX and it is listed on the New York Stock Exchange, Inc. exchange.
CFX stock is listed on the New York Stock Exchange, Inc. exchange.
19 analysts have analysed CFX and the average price target is 51.43 null. This implies a price increase of 31.66% is expected in the next year compared to the current price of 39.06. Check the COLFAX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
COLFAX CORP (CFX) has a market capitalization of 6.10B null. This makes CFX a Mid Cap stock.
COLFAX CORP (CFX) currently has 16200 employees.
COLFAX CORP (CFX) has a support level at 37.29 and a resistance level at 40.03. Check the full technical report for a detailed analysis of CFX support and resistance levels.
The Revenue of COLFAX CORP (CFX) is expected to grow by 7.2% in the next year. Check the estimates tab for more information on the CFX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CFX does not pay a dividend.
COLFAX CORP (CFX) will report earnings on 2022-04-28, before the market open.
The PE ratio for COLFAX CORP (CFX) is 18.34. This is based on the reported non-GAAP earnings per share of 2.13 and the current share price of 39.06 null. Check the full fundamental report for a full analysis of the valuation metrics for CFX.
ChartMill assigns a technical rating of 1 / 10 to CFX. When comparing the yearly performance of all stocks, CFX is a bad performer in the overall market: 61.5% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to CFX. CFX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CFX reported a non-GAAP Earnings per Share(EPS) of 2.13. The EPS increased by 53.24% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 1.86% | ||
ROA | 0.84% | ||
ROE | 1.55% | ||
Debt/Equity | 0.45 |
ChartMill assigns a Buy % Consensus number of 79% to CFX. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 241.51% and a revenue growth 7.2% for CFX